FR09C0022I1 - - Google Patents

Info

Publication number
FR09C0022I1
FR09C0022I1 FR09C0022C FR09C0022I1 FR 09C0022 I1 FR09C0022 I1 FR 09C0022I1 FR 09C0022 C FR09C0022 C FR 09C0022C FR 09C0022 I1 FR09C0022 I1 FR 09C0022I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR09C0022I1 publication Critical patent/FR09C0022I1/fr
Application granted granted Critical
Publication of FR09C0022I2 publication Critical patent/FR09C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/77Polymers containing oxygen of oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
FR09C0022C 1996-12-11 2009-05-25 Active FR09C0022I2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3282096P 1996-12-11 1996-12-11
US08/886,933 US6071904A (en) 1996-12-11 1997-07-02 Process for manufacturing ophthalmic suspensions
PCT/US1997/015727 WO1998025620A1 (en) 1996-12-11 1997-09-05 Process for manufacturing ophthalmic suspensions

Publications (2)

Publication Number Publication Date
FR09C0022I1 true FR09C0022I1 (es) 2009-09-25
FR09C0022I2 FR09C0022I2 (es) 2010-06-11

Family

ID=26708929

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0022C Active FR09C0022I2 (es) 1996-12-11 2009-05-25

Country Status (14)

Country Link
US (1) US6071904A (es)
EP (1) EP0941094B1 (es)
JP (1) JP3611863B2 (es)
AT (1) ATE209917T1 (es)
CA (1) CA2274680C (es)
DE (2) DE69708912T2 (es)
DK (1) DK0941094T3 (es)
ES (1) ES2169416T3 (es)
FR (1) FR09C0022I2 (es)
HK (1) HK1019704A1 (es)
LU (1) LU91554I2 (es)
NL (1) NL300388I2 (es)
PT (1) PT941094E (es)
WO (1) WO1998025620A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001365A1 (en) * 1998-06-30 2000-01-13 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Prolonged release ophthalmic compositions containing a fluoroquinolone
US20030008853A1 (en) * 2001-05-21 2003-01-09 Alcon, Inc. Method for treating dry eye disorders
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
DE60213230T2 (de) 2001-05-21 2006-11-23 Alcon Inc. Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
AU2002308760B2 (en) 2001-05-21 2006-05-11 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
EP1480636B1 (en) * 2002-03-01 2007-04-18 Novagali Pharma SA Self emulsifying drug delivery systems for taxoids
ES2301964T3 (es) 2003-01-21 2008-07-01 Senju Pharmaceutical Co., Ltd. Preparado liquido acuoso que contiene acido 2-amino-3-(4-bromobenzoil)fenilacetico.
DE602005026225D1 (de) * 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
PL1891939T3 (pl) * 2006-07-28 2014-01-31 Santen Sas Kompozycje zawierające czwartorzędowe związki amonowe
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸-多元醇錯合物之水性藥學組成物
MX2012006401A (es) * 2009-12-03 2012-07-10 Lupin Ltd Proceso para preparar composiciones oftalmicas farmaceuticas.
EP2394637A1 (en) * 2010-05-21 2011-12-14 Zaklady Farmaceutyczne Polpharma SA Process for obtaining sterile brinzolamide suspensions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
CA2807081C (en) 2010-07-29 2018-09-18 Allergan, Inc. Preservative free bimatoprost and timolol solutions
WO2012053011A2 (en) 2010-10-18 2012-04-26 Usv Limited Ophthalmic compositions comprising brinzolamide
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
EP2638909A1 (en) 2012-03-15 2013-09-18 Azad Pharmaceutical Ingredients AG Process for preparing sterile Brinzolamide
GR1007906B (el) * 2012-03-22 2013-05-30 Φαρματεν Αβεε, Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
ES2624250T3 (es) 2012-05-09 2017-07-13 Icrom Spa Producción de brinzolamida farmacéutica estéril
US20150119386A1 (en) * 2012-05-21 2015-04-30 Aurobindo Pharma Limited Process for preparing opthalmic suspension of brinzolamide
US9649319B2 (en) 2012-10-11 2017-05-16 Indoco Remedies Limited Process for manufacturing sterile brinzolamide ophthalmic suspension
CN104721136A (zh) * 2013-02-21 2015-06-24 四川大学 一种布佐林胺眼用纳米混悬剂及其制备方法
US9801813B2 (en) * 2013-10-17 2017-10-31 Sentiss Pharma Private Limited Preservative-free ophthalmic pharmaceutical formulation
US9820991B2 (en) * 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
WO2015068105A1 (en) 2013-11-08 2015-05-14 Sentiss Pharma Private Limited An improved process for manufacturing sterile ophthalmic pharmaceutical suspensions
ES2838756T3 (es) 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
PL407710A1 (pl) * 2014-03-28 2015-10-12 Instytut Farmaceutyczny Sposób wytwarzania preparatu kropli do oczu w postaci zawiesiny zawierającej brynzolamid i preparat wytworzony tym sposobem
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
ES2954412T3 (es) 2014-10-20 2023-11-22 Sentiss Pharma Private Ltd Solución oftálmica
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
CN107582519A (zh) * 2017-06-01 2018-01-16 合肥远志医药科技开发有限公司 一种布林佐胺滴眼液制剂及其制备方法
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
US11298360B2 (en) 2018-04-25 2022-04-12 Shilpa Medicare Limited Ophthalmic compositions of brinzolamide
GR1009616B (el) * 2018-07-20 2019-10-11 Φαρματεν Α.Β.Ε.Ε. Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου
WO2020240451A1 (en) 2019-05-29 2020-12-03 Lupin Limited In-situ gelling nanoemulsion of brinzolamide
US20220105101A1 (en) * 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Efficient brinzolamide and brimonidine compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
RO113612B1 (ro) * 1991-04-17 1998-09-30 Merck & Co Inc Compozitie oftalmica
DK0625903T3 (da) * 1992-02-21 1999-05-10 Alcon Lab Inc Topiske antiglaukompræparater omfattende carbonsyreanhydraseinhibitorer og beta-blokkere
US5362758A (en) * 1992-09-18 1994-11-08 Pfizer Inc. Ophthalmic piroxicam solution
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system

Also Published As

Publication number Publication date
EP0941094A1 (en) 1999-09-15
DE69708912D1 (de) 2002-01-17
DE122009000016I1 (de) 2009-06-25
AU718079B2 (en) 2000-04-06
CA2274680A1 (en) 1998-06-18
HK1019704A1 (en) 2000-02-25
CA2274680C (en) 2003-11-18
NL300388I2 (nl) 2010-02-01
US6071904A (en) 2000-06-06
AU4183897A (en) 1998-07-03
EP0941094B1 (en) 2001-12-05
LU91554I2 (fr) 2009-06-22
JP3611863B2 (ja) 2005-01-19
ATE209917T1 (de) 2001-12-15
DE69708912T2 (de) 2002-04-11
FR09C0022I2 (es) 2010-06-11
DK0941094T3 (da) 2002-01-07
NL300388I1 (nl) 2009-07-01
WO1998025620A1 (en) 1998-06-18
PT941094E (pt) 2002-05-31
JP2000501749A (ja) 2000-02-15
ES2169416T3 (es) 2002-07-01

Similar Documents

Publication Publication Date Title
FR09C0022I2 (es)
ITMI960645V0 (es)
IN185038B (es)
IN189774B (es)
IN192786B (es)
FR11C0047I1 (es)
IN192277B (es)
IN192921B (es)
ITMI960401A0 (es)
IN187379B (es)
ITMI960598V0 (es)
IN190435B (es)
IN189446B (es)
IN187188B (es)
ITMI960473V0 (es)
ITFI960043A0 (es)
ITAN960028V0 (es)
ITMI960492V0 (es)
IN185226B (es)
IN186278B (es)
IN191969B (es)
IN186517B (es)
IN186611B (es)
CN3044349S (es)
CN3046379S (es)